(Q22252976)

7 February 2023

2

J R Geddes

J R

Geddes

1 reference

7 February 2023

Karine Macritchie

1

K

Macritchie

1 reference

7 February 2023

Jan Scott

series ordinal

3

author given names

J

author last names

Scott

1 reference

7 February 2023

D R Haslam

series ordinal

4

author given names

D

author last names

Haslam

1 reference

7 February 2023

Mauricio Silva de Lima

series ordinal

5

author given names

M

author last names

de Lima

1 reference

Cochrane Database of Systematic Reviews

7 February 2023

language of work or name

English

0 references

publication date

20 January 2003

0 references

published in

0 references

issue

1

0 references

page(s)

CD004052

0 references

cites work

Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Depression during mania. Treatment response to lithium or divalproex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

A double-blind comparison of valproate and lithium in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Valproate in the treatment of acute mania. A placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

A naturalistic comparison of adverse effects between slow titration and loading of divalproex sodium in psychiatric inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Olanzapine: a review of its use in the treatment of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Role of newer medications for bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

A diagnostic interview: the schedule for affective disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Anticonvulsants in the treatment of mood disorders: assessing current and future roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

The hazards of scoring the quality of clinical trials for meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Lithium: evidence reconsidered

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Is there a lithium withdrawal syndrome? An examination of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

A rating scale for mania: reliability, validity and sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

Plasma GABA predicts acute response to divalproex in mania

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

Valproic acid amide in the treatment of affective and schizoaffective disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD004052

1 reference

7 January 2021

Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: an open clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

Naturalistic experience with the use of divalproex sodium on an in-patient unit for adolescent psychiatric patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

Relation of serum valproate concentration to response in mania

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

Use of mood stabilizers by hospitalized geriatric patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

Generalisability of results from randomised drug trials. A trial on antimanic treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004052

7 January 2021

10.1002/14651858.CD004052

Identifiers

DOI

0 references

Fatcat ID

release_fvr3rberc5h4hcn5hf6zxn3uhy

0 references